Find A Multiple Myeloma Trial

This study is testing a decision support tool called PRIME for adults aged 60 and older who are new patients at blood cancer clinics, including those with multiple myeloma. The tool helps patients communicate their values and preferences to their doctors, which may lead to treatment decisions that better match what matters most to each patient.

This study is testing a new CAR T-cell therapy called GC012F that targets two proteins (CD19 and BCMA) on cancer cells in adults with multiple myeloma that has returned or stopped responding to treatment. This treatment is unique because it attacks cancer cells through two different targets at the same time, which may help prevent the cancer from developing resistance and provide better outcomes for patients whose multiple myeloma has not responded to at least three previous treatments.

This study is testing a combination treatment of carfilzomib, iberdomide, and dexamethasone for patients with newly diagnosed multiple myeloma who are eligible for stem cell transplant. This research is unique because it combines a new drug called iberdomide with proven multiple myeloma treatments, which may help patients achieve better responses and potentially improve their chances of successful transplant outcomes.

This study is testing whether two cancer treatments, Teclisma (teclistamab) and Talvey (talquetamab), can be safely given to Multiple Myeloma patients in an outpatient clinic setting rather than requiring hospitalization. The research focuses on whether patients can receive these treatments at home while being monitored by a caregiver, which could make these effective therapies more convenient and accessible for Multiple Myeloma patients who have already tried other treatments.

This study tests stem cell transplant using donor cells combined with chemotherapy or radiation to treat patients with blood cancers including multiple myeloma, leukemia, and lymphoma. The treatment uses a special combination of medications after transplant to help prevent complications, potentially offering a curative option for patients whose cancer has returned or not responded well to other treatments.

This study compares two treatments for people with high-risk smoldering multiple myeloma: the drug Teclistamab versus a combination of Lenalidomide and Dexamethasone. The research aims to determine which treatment is more effective at preventing the progression to active multiple myeloma, potentially offering patients with this early-stage blood cancer a way to delay or prevent their disease from becoming symptomatic.

This study tests a combination of three medications (elotuzumab, iberdomide, and dexamethasone) in patients with multiple myeloma that has returned or stopped responding to treatment, specifically after they have received a CAR-T cell therapy called ide-cel. The research aims to determine if this three-drug combination can effectively control the cancer in patients who have already tried at least four previous treatments and recently completed ide-cel therapy.

This study tests FDA-approved targeted cancer drugs in patients with advanced Multiple Myeloma whose tumors have specific genetic changes that may respond to these treatments. What makes this study unique is that it matches patients to treatments based on their tumor's genetic profile rather than cancer type alone, potentially offering new treatment options when standard therapies are no longer working.

This study examines whether a plant-based diet or dietary supplements (omega-3, curcumin, or probiotics) can change butyrate levels in the stool of people with smoldering multiple myeloma over two weeks. This research is unique because it focuses on how simple dietary changes might affect gut health in patients with this early form of multiple myeloma, potentially offering a natural approach to support their health before the disease progresses.

This study tests a combination treatment approach for people with newly diagnosed, standard-risk multiple myeloma who are candidates for stem cell transplant, comparing Dara-RVd (daratumumab with lenalidomide, bortezomib, and dexamethasone) followed by Tec-RVd (teclistamab with the same three drugs). The unique aspect of this research is evaluating whether switching from one targeted antibody therapy to another after three treatment cycles provides a safe and potentially more effective treatment strategy for multiple myeloma patients.

This study is testing Arlocabtagene Autoleucel, a CAR T cell therapy that uses a patient's own immune cells that have been genetically modified to fight cancer, in adults with multiple myeloma that has returned or stopped responding to treatment. This treatment is unique because it targets a specific protein called GPRC5D on myeloma cells, offering a new approach for patients who have already tried at least three different types of standard treatments including immunomodulatory drugs, proteasome inhibitors, and anti-CD38 antibodies.

This study is testing a new treatment called BMS-986453 combined with cyclophosphamide and fludarabine in patients with multiple myeloma that has returned or stopped responding to previous treatments. This research is unique because it explores a novel drug combination that may offer new hope for patients whose cancer has become resistant to standard therapies.

This study tests lower doses of the drug cyclophosphamide given after blood stem cell transplants in patients with blood cancers like leukemia, lymphoma, and multiple myeloma to prevent graft-versus-host disease. The research aims to find the smallest effective dose that can protect patients from this serious transplant complication while reducing side effects, potentially improving outcomes for multiple myeloma patients and others receiving stem cell transplants.

This study is testing a CMV vaccine given to stem cell donors to prevent cytomegalovirus (CMV) infections in patients with blood cancers who are receiving stem cell transplants from related family donors. By vaccinating the donors before they donate their stem cells, the study aims to transfer protective immunity against CMV to transplant patients, potentially reducing serious infections that commonly occur when the immune system is weakened after transplant.

This study tests a combination of three cancer medicines (selinexor, carfilzomib, and dexamethasone) in patients whose multiple myeloma has returned or stopped responding to previous treatments. The research aims to find the safest dose of this three-drug combination and may offer a new treatment option for patients who have already tried at least two other therapies, including specific types of multiple myeloma drugs.

This study tests combining stem cell transplant with CAR T-cell therapy for patients with blood cancers like multiple myeloma that have returned or stopped responding to treatment. This unique approach may help multiple myeloma patients by using their own healthy stem cells alongside engineered immune cells to potentially improve treatment effectiveness and recovery.

This study is testing a new treatment called kappa-CD28 T cells for patients with multiple myeloma, chronic lymphocytic leukemia, or B-cell lymphoma that has come back or not responded to previous treatments. The treatment combines two cancer-fighting approaches by taking a patient's own T cells (immune cells) and genetically modifying them with both an antibody that targets kappa proteins on cancer cells and a CD28 protein that helps the T cells survive longer in the body, potentially making them more effective at fighting cancer.

This study is testing a combination of four medications - isatuximab (an investigational drug), lenalidomide, bortezomib, and dexamethasone - for patients with newly diagnosed multiple myeloma who are eligible for stem cell transplant. The research aims to determine if adding isatuximab to the standard three-drug treatment is safe and more effective than current therapies, potentially offering patients with this blood cancer a better treatment option before undergoing stem cell transplant.

This study is testing a new cancer drug called etentamig, given alone or with other standard multiple myeloma medications, in adults with newly diagnosed or relapsed/refractory multiple myeloma. The research aims to find the safest and most effective dose of etentamig and may provide patients with a new treatment option that could help control their cancer when combined with existing therapies.

This study is testing a new treatment called OPN-6602, either alone or combined with dexamethasone, for patients with multiple myeloma that has come back or stopped responding to previous treatments. The study focuses on patients who have already tried at least three different types of standard treatments, offering a potential new option when other therapies are no longer working effectively.

This study is testing whether isatuximab, a cancer drug already approved for multiple myeloma, can improve kidney function in patients with monoclonal gammopathy of renal significance (MGRS), a rare condition where abnormal proteins damage the kidneys. This research is unique because it explores using an existing cancer treatment to protect kidney function in patients who don't have cancer but have kidney damage from similar abnormal blood proteins.

This study tests a combination of two drugs, mirdametinib and sirolimus, in patients with relapsed or treatment-resistant multiple myeloma who have specific genetic changes (RAS mutations). The combination specifically targets cancer cells with these genetic changes and may provide a new treatment option for patients whose myeloma has stopped responding to standard therapies.

This study examines the real-world experience of adults with relapsed or refractory multiple myeloma who are receiving standard treatment with isatuximab, a cancer medication given through an IV. The study is unique because it uses digital health coaching, wearable devices like Fitbits, and detailed patient questionnaires to better understand how this treatment affects patients' daily lives, quality of life, and treatment adherence in real-world settings.

This study tests a combination of isatuximab and lenalidomide as maintenance therapy for multiple myeloma patients who still have detectable cancer cells (minimal residual disease) after receiving an autologous stem cell transplant. The research focuses specifically on patients with remaining cancer traces to determine if this dual-drug approach can help eliminate residual disease and potentially improve long-term outcomes compared to standard single-drug maintenance treatments.

This study is testing whether adding a medication called CYT107 (recombinant human interleukin-7) after stem cell transplant can help multiple myeloma patients by boosting their immune system recovery. The treatment may help the body better fight remaining cancer cells and reduce infections by strengthening the patient's T-cells, which are important immune system defenders that are weakened during transplant treatment.

This study examines a combined bone marrow and kidney transplant from a partially matched family donor for patients who have both blood disorders (like multiple myeloma, leukemia, or lymphoma) and chronic kidney disease. This approach may reduce the risk of organ rejection and decrease the need for long-term anti-rejection medications, while potentially treating both conditions with a single treatment approach.

This study tests different methods to help cancer patients, including those with multiple myeloma, take their oral cancer medications as prescribed. The research focuses on patients from diverse backgrounds with limited health literacy and examines multiple approaches to improve medication adherence, which could lead to better treatment outcomes for multiple myeloma patients who struggle to consistently take their prescribed oral therapies.

This study tests whether adding linvoselitamab to lenalidomide maintenance therapy can improve treatment outcomes for patients with newly diagnosed multiple myeloma who have already completed initial treatment. The combination aims to eliminate remaining cancer cells in the body and help patients achieve or maintain a state where no detectable cancer remains, potentially extending the time their disease stays controlled.

This study is testing new combinations of cancer medicines (elranatamab with carfilzomib and dexamethasone, or elranatamab with maplirpacept) in patients whose multiple myeloma has come back or stopped responding to previous treatments. The study is unique because it explores combining elranatamab, a newer targeted therapy, with other effective multiple myeloma drugs to potentially provide better treatment options for patients who have limited choices after their cancer has become resistant to standard therapies.

This study examines the drug elranatamab given before and after stem cell transplant in patients with newly diagnosed, high-risk multiple myeloma who are eligible for transplant. The study uses a unique approach called MRD-guided therapy, where treatment decisions after transplant are based on whether minimal residual disease (tiny amounts of cancer) can still be detected, potentially leading to more personalized and effective treatment for high-risk patients.

This study tests IDP-023, a new cancer treatment, either alone or combined with antibody therapies, in patients with advanced blood cancers including multiple myeloma that has returned or stopped responding to at least three previous treatments. This research is unique because it's the first time IDP-023 has been tested in humans, and it may offer multiple myeloma patients a new treatment option when their cancer no longer responds to standard therapies.

This study examines how giving cancer patients, including those with multiple myeloma, choices about what types of genetic test results they want to receive from their cancer research participation affects their experience. The research focuses on understanding how patient involvement in deciding whether to learn about inherited cancer mutations or cancer cell characteristics impacts their knowledge, expectations, and satisfaction with their care.

This study examines whether multiple myeloma patients who have responded well to teclistamab treatment can safely stop taking the medication after 6-9 months and only restart it if their cancer shows signs of returning. This approach could reduce the risk of infections and other side effects that come with continuous treatment, while researchers will also study factors that might predict which patients can successfully take treatment breaks.

This study tests a combination of three drugs - leflunomide, pomalidomide, and dexamethasone - in patients with multiple myeloma that has returned or stopped responding to previous treatments. The research aims to determine if adding leflunomide to the standard pomalidomide and dexamethasone combination may provide better cancer control for patients whose disease has progressed despite prior therapies including proteasome inhibitors and immunomodulatory drugs.

This study is testing ABBV-453, a new oral medication, either alone or combined with existing multiple myeloma treatments in adults whose cancer has returned or stopped responding to previous therapies. The research focuses on finding the safest and most effective dose of ABBV-453, which works differently from current treatments by targeting specific proteins that help cancer cells survive, potentially offering a new treatment option for patients with limited alternatives.

This study tests a combination treatment of lenalidomide, dexamethasone, and isatuximab for multiple myeloma patients who still have detectable cancer cells in their bone marrow after stem cell transplant. The study aims to eliminate these remaining cancer cells (called minimal residual disease) to potentially improve long-term outcomes and prevent the cancer from returning.

This study is testing AZD0305, a new cancer medicine, either alone or combined with other anticancer drugs in patients with multiple myeloma that has returned or stopped responding to previous treatments. What makes this study unique is that it focuses on patients who have already tried at least three different types of standard treatments, offering a potential new treatment option for those with hard-to-treat multiple myeloma.

This study is testing Darzalex Faspro (daratumumab and hyaluronidase-fihj) given before a standard stem cell transplant in adults who have high levels of antibodies that could cause their body to reject their donor's stem cells. This treatment approach may help lower these harmful antibodies to safe levels, allowing patients with blood cancers like Multiple Myeloma to successfully receive life-saving transplants that would otherwise be too risky due to transplant rejection.

This study examines whether a plant-based diet combined with omega-3 and curcumin supplements can help people with early blood cancer conditions called MGUS (monoclonal gammopathy of undetermined significance) or smoldering multiple myeloma. The research focuses on measuring changes in butyrate levels in stool samples, which may provide insights into how dietary changes could potentially slow the progression of these conditions to active multiple myeloma.

This study examines allogeneic stem cell transplantation using a reduced-intensity conditioning regimen and post-transplant cyclophosphamide for patients with various blood cancers including multiple myeloma who have relapsed or high-risk disease. The treatment is unique because it uses a gentler preparation approach that may allow older or less healthy patients to receive transplants, while the post-transplant cyclophosphamide helps prevent graft-versus-host disease and may allow the use of partially matched family donors when fully matched donors are not available.

This study is testing belantamab mafodotin as a maintenance therapy for multiple myeloma patients who have had their cancer return (relapsed or refractory) and received a stem cell transplant using their own cells. The study aims to determine if this targeted antibody-drug treatment can help prevent the cancer from coming back after transplant and establish its safety profile in this specific patient population.

This study examines whether nivolumab, an immunotherapy drug, can improve treatment response in patients with relapsed or refractory multiple myeloma who achieved only a partial response to idecabtagene vicleucel (a CAR-T cell therapy). This research is unique because it tests whether adding immunotherapy after CAR-T treatment can help deepen the cancer response, potentially offering multiple myeloma patients a way to achieve better disease control when their initial CAR-T therapy doesn't provide the ideal outcome.

This study is testing Selinexor, an oral medication, in patients with smoldering multiple myeloma who have intermediate to high risk of their disease progressing to active multiple myeloma. The study aims to determine if early treatment with Selinexor can delay or prevent the progression from smoldering multiple myeloma to symptomatic multiple myeloma, potentially helping patients avoid the complications associated with active disease.

This study compares Rezafungin, a new antifungal medication given through an IV, to standard antifungal treatments for preventing serious fungal infections in adults receiving bone marrow transplants for blood cancers and other blood disorders. The research is particularly important because it tests whether a single weekly injection of Rezafungin can provide the same protection as daily medications, potentially offering patients a more convenient treatment option with fewer side effects during their recovery from transplant.

This study tests a four-drug combination treatment (iberdomide, daratumumab, carfilzomib, and dexamethasone) for patients with multiple myeloma that has returned or stopped responding to previous treatments. The study is unique because it combines a new oral medication (iberdomide) with three established multiple myeloma drugs, which may help shrink tumors more effectively and potentially achieve deeper remissions than current standard treatments.

This study is testing a combination treatment called CyBorD (cyclophosphamide, bortezomib, and dexamethasone) plus daratumumab in people with kidney disease caused by abnormal proteins from multiple myeloma or related blood cell disorders. The research aims to determine whether this four-drug combination can safely and effectively protect kidney function while treating the underlying blood disorder that damages the kidneys.

This study tests a combination of two FDA-approved cancer drugs, belantamab mafodotin and elotuzumab, in patients with multiple myeloma that has returned or stopped responding to at least three previous treatments. This is the first study to explore whether combining these two targeted therapies together can provide better results than using either drug alone, potentially offering a new treatment option for patients with hard-to-treat multiple myeloma.

This study tests whether elranatemab (a targeted cancer drug) can help maintain remission in multiple myeloma patients after stem cell transplant, using special blood tests to guide treatment decisions. The unique approach uses personalized monitoring to detect tiny amounts of remaining cancer cells and adjust treatment accordingly, which may help patients stay in remission longer than standard care.

This study tests a new approach to treating people with newly diagnosed multiple myeloma by using advanced testing to measure minimal residual disease (MRD) - the tiny amounts of cancer that may remain after treatment - to guide treatment decisions. The study is unique because it personalizes treatment based on how well each patient responds, potentially allowing some patients to avoid stem cell transplant if they achieve very low cancer levels with initial therapy, while others receive enhanced treatment combinations to improve their outcomes.

This study tests a personalized T-cell therapy using the patient's own immune cells that are modified to target specific mutations found in multiple myeloma and other blood cancers. The therapy is unique because it creates individualized treatment by engineering T-cells to recognize neoantigens (abnormal proteins) produced by each patient's specific cancer mutations, potentially offering a new approach for patients with hard-to-treat blood cancers who have limited treatment options.

This study compares two different drug combinations for treating patients with relapsed or refractory multiple myeloma who have received 1-3 previous treatments and were previously treated with lenalidomide: one combination uses mezigdomide with bortezomib and dexamethasone, while the other uses pomalidomide with bortezomib and dexamethasone. This research is important because it tests whether mezigdomide, a newer medication, can provide better treatment outcomes than the current standard combination for multiple myeloma patients whose cancer has returned or stopped responding to previous therapies.

This study is testing the combination of two targeted drugs, dabrafenib and trametinib, in patients with multiple myeloma that has returned or stopped responding to at least two previous treatments. What makes this research unique is that it specifically focuses on patients whose cancer cells have certain genetic mutations (BRAF, KRAS, or NRAS), which may make their tumors more likely to respond to these targeted therapies that block specific cancer growth pathways.

This study tests a combination of two medicines, iberdomide and teclistamab, in patients with multiple myeloma that has returned after treatment or has not responded to previous therapies. This research aims to find the safest and most effective dose of these drugs working together, potentially offering a new treatment option that may help the body's immune system better fight multiple myeloma cancer cells.

This study is testing a combination of two drugs, etentamig (given through an IV) and iberdomide (taken by mouth), for adults with multiple myeloma that has returned or stopped responding to previous treatments. This research is unique because it combines a new investigational drug with a cereblon E3 ligase modulator, which may offer a different approach to fighting multiple myeloma and could potentially help patients whose cancer has become resistant to other therapies.

This study compares two treatment approaches for people newly diagnosed with multiple myeloma: a combination of four medications (daratumumab, bortezomib, lenalidomide, and dexamethasone) followed by either CAR-T cell therapy or an autologous stem cell transplant. This research is unique because it directly tests whether CAR-T cell therapy, which uses genetically modified immune cells to fight cancer, can work as well as or better than the standard stem cell transplant approach for multiple myeloma patients.

This study tests a combination of three medications - elotuzumab, CC-92480, and dexamethasone - for patients with multiple myeloma that has returned or stopped responding to treatment, specifically after they have already received CD38- and BCMA-targeted therapies. The study focuses on finding new treatment options for patients whose cancer has become resistant to newer immunotherapy treatments, potentially offering hope when other advanced therapies have failed.

This study examines how genetic changes may affect the risk of developing low blood cell counts (cytopenia) in patients with multiple myeloma or certain blood cancers who receive CAR-T cell therapy. The research aims to identify specific gene mutations that could help doctors predict which patients are more likely to experience prolonged low blood cell counts after this advanced immunotherapy treatment.

This study is testing a combined coping skills training and activity coaching program called "Step Up" for people with blood cancers who have received stem cell transplants or CAR-T cell therapy and are experiencing symptoms like pain, fatigue, and stress. The program uniquely combines in-person sessions with mobile health technology to help patients better manage their symptoms and increase their physical activity levels, which may lead to improved daily functioning and reduced disability.

This study is testing whether leflunomide, a medication that reduces immune system activity, can help African-American and European-American patients with high-risk smoldering multiple myeloma (a condition that can develop into full multiple myeloma cancer). The research focuses specifically on different racial groups because they may respond differently to treatment, potentially helping doctors better understand how to delay or prevent the progression to active multiple myeloma in these populations.

This study examines vitamin D supplementation combined with lenalidomide as maintenance therapy for multiple myeloma patients after stem cell transplant. The research aims to determine if adding vitamin D to standard treatment can improve immune system recovery and help patients live longer without their cancer returning compared to treatment without vitamin D supplementation.

This study is testing mezigdomide (CC-92480), an oral cancer drug, in patients with multiple myeloma that has returned after receiving CAR T-cell therapy (idecabtagene vicleucel/Abecma). The research aims to determine if giving mezigdomide after CAR T-cell treatment may help the modified immune cells stay active in the body longer, potentially extending the time before the cancer comes back.

This study is testing LP-118, an oral medication taken once daily, in patients with various relapsed or refractory blood cancers including Multiple Myeloma, leukemia, lymphoma, and related conditions. The study is unique because it evaluates LP-118 as a convenient oral treatment option for patients who have exhausted standard therapies, potentially offering a new approach for Multiple Myeloma patients and others with blood cancers who have limited treatment options remaining.

This study is testing whether specialized health assessments and targeted interventions (including physical therapy, nutrition support, and cognitive training) can help patients aged 60 and older recover better after receiving CAR-T cell therapy for multiple myeloma or B-cell non-Hodgkin lymphoma. This approach may help older adults experience fewer side effects and recover their strength and daily functioning more quickly after this advanced cancer treatment by identifying and addressing health issues before they become problems.

This study compares linvoseltuximab, a new experimental drug, to a combination of three standard cancer drugs (elotuzumab, pomalidomide, and dexamethasone) in adults with multiple myeloma that has returned or stopped responding to treatment after 1-4 previous therapies. The research aims to determine if linvoseltuximab alone can work as well as or better than the three-drug combination, potentially offering patients a simpler treatment option with fewer side effects while maintaining effectiveness against their cancer.

This study is testing a web-based decision tool to help patients with colorectal cancer, multiple myeloma, and cholangiocarcinoma make informed choices about receiving genetic test results from their cancer care. The study is unique because it focuses specifically on helping patients with rare cancers understand and decide what types of genetic information they want to learn about, which could lead to more personalized and patient-centered care decisions.

This study tests the safety and effectiveness of narazaciclib (ON 123300) combined with dexamethasone in patients with multiple myeloma that has returned or stopped responding to treatment. This research evaluates a first-in-class oral medication that targets specific proteins (CDK4 and ARK5) involved in cancer cell growth, potentially offering a new treatment option for multiple myeloma patients who have already tried standard therapies.

This study examines umbilical cord blood transplantation using a conditioning treatment with chemotherapy drugs and radiation for patients with blood cancers including multiple myeloma, leukemias, and lymphomas. The treatment uses cord blood from unrelated donors, which may provide a transplant option for patients who cannot find a matching bone marrow donor and could offer multiple myeloma patients a potentially life-saving treatment when other therapies have not been successful.

This study is testing elranatamab, a targeted therapy drug, in patients with relapsed and refractory multiple myeloma who have previously received idecabtagene vicleucel (a CAR-T cell therapy). The research aims to determine if elranatamab can reduce the risk of disease progression after CAR-T cell treatment, potentially offering patients a new treatment option to help maintain their response and delay cancer recurrence.

This study is testing a new treatment called P-BCMA-ALLO1 CAR-T cells for patients with multiple myeloma that has returned or stopped responding to previous treatments, including proteasome inhibitors, immunomodulatory drugs, and anti-CD38 therapy. What makes this treatment unique is that it uses specially modified immune cells from a donor (allogeneic) rather than the patient's own cells, which could make the therapy more widely available and potentially work faster for multiple myeloma patients.

This study is testing radiation therapy as a salvage treatment for patients with relapsed or refractory multiple myeloma whose disease has returned after receiving CAR-T cell therapy that targets BCMA (a protein found on myeloma cells). The study aims to determine if targeted radiation to up to five myeloma tumor sites can help patients respond to treatment again and may provide a new option for controlling the disease when CAR-T therapy is no longer working effectively.

This study is testing specially modified natural killer (NK) immune cells combined with chemotherapy for patients with blood cancers like multiple myeloma, leukemia, and lymphoma that have returned or stopped responding to treatment. The NK cells are engineered to better recognize and attack cancer cells that have a specific protein called CD70, which may help the immune system fight these hard-to-treat blood cancers more effectively.

This study is testing the combination of talquetamab and lenalidomide as maintenance therapy for multiple myeloma patients who have received stem cell transplant. This approach is unique because it combines a newer targeted therapy (talquetamab) with an established treatment (lenalidomide) to help prevent the cancer from returning after transplant, potentially offering better long-term disease control than current maintenance options.

This study tests a combination of three cancer drugs (selinexor, venetoclax, and dexamethasone) in patients with relapsed or treatment-resistant multiple myeloma that has a specific genetic change called t(11;14). The research specifically targets patients whose cancer has this genetic marker and has not responded to previous treatments, aiming to determine if this drug combination can provide better anti-cancer effects than current therapies.

This study is testing a new preparation method using low-dose radiation and chemotherapy before giving ciltacabtagene autoleucel (a CAR T-cell therapy) to multiple myeloma patients who have kidney problems. This research is unique because it specifically includes multiple myeloma patients with kidney damage who are usually excluded from other studies, potentially offering these patients access to an effective treatment option.

This study is testing a combination of low-dose selinexor and choline salicylate in patients with multiple myeloma that has returned or stopped responding to treatment, as well as patients with certain types of lymphoma and blood cell cancers. This research is unique because it combines two different drugs - selinexor, which blocks a protein needed for cancer cell growth, and choline salicylate, an anti-inflammatory drug - to potentially offer a new treatment option for multiple myeloma patients who have already tried several other therapies.

This study is testing a radioactive imaging agent called Iodine-124 Evuzumitide in patients with systemic amyloidosis, a condition where abnormal proteins build up in organs and tissues. The research uses advanced PET/MRI scans to create detailed pictures showing where amyloid deposits are located in the body and how they affect organ function, which could help doctors better diagnose and monitor this disease.

This study is testing an investigational oral medication called KTX-1001 (an MMSET inhibitor) alone or in combination with standard treatments for adults with multiple myeloma that has returned or stopped responding to previous therapies. The study focuses on a unique approach by targeting a specific protein (MMSET) that helps cancer cells grow, which may offer a new treatment option for patients whose cancer has become resistant to at least three prior therapies including proteasome inhibitors, immunomodulatory drugs, and anti-CD38 antibodies.

This study compares two treatment combinations for people with newly diagnosed multiple myeloma who cannot receive stem cell transplants: belantamab mafodotin combined with lenalidomide and dexamethasone (BRd) versus daratumumab with lenalidomide and dexamethasone (DRd). The research aims to determine if the BRd combination can help patients live longer without their cancer getting worse and achieve better elimination of remaining cancer cells compared to the current standard DRd treatment.

This study tests a combination of four medications—carfilzomib, lenalidomide, dexamethasone, and belantamab mafodotin—for patients with multiple myeloma, including those with newly diagnosed high-risk disease and those whose cancer has returned or not responded to previous treatments. This research is unique because it combines a newer targeted therapy (belantamab mafodotin) with established multiple myeloma treatments, potentially offering patients with hard-to-treat forms of the disease a more effective treatment option.

This study is testing a smartphone app called STAMP+CBT that combines pain medication support with cognitive behavioral therapy techniques for patients with advanced cancer (including multiple myeloma) who have chronic pain and are taking opioid medications. The app is unique because it integrates both psychological and medication-based approaches to pain management in one mobile platform, potentially offering patients more comprehensive and accessible pain relief tools.

This study is testing elranatamab, a new targeted therapy, both alone and in combination with daratumumab for patients with multiple myeloma who have already received other treatments including lenalidomide. The study is unique because it compares elranatamab as a single treatment against standard combination therapy, while also testing enhanced infection prevention measures to improve patient safety during treatment.

This study tests a combination of medications (cyclophosphamide, bortezomib, and maraviroc) to prevent graft-versus-host disease after bone marrow transplant in people living with HIV who have blood cancers like multiple myeloma. The study is unique because it specifically focuses on HIV-positive patients and uses a new three-drug combination to potentially improve transplant outcomes and reduce complications in this population.

This study tests a combination of cancer drugs including carfilzomib, cyclophosphamide, dexamethasone, and G-CSF to help collect stem cells from multiple myeloma patients who need stem cell transplants. The research aims to find the safest and most effective dose of carfilzomib when combined with these other medications to improve stem cell collection for patients preparing for their own stem cell transplant.

This study examines whether adding specialized palliative care support can improve quality of life for patients with blood cancers like multiple myeloma, lymphoma, or leukemia who are receiving adoptive cellular therapy (a type of immunotherapy treatment). This research is unique because it specifically focuses on how palliative care can help manage symptoms and improve the treatment experience during advanced cellular therapy, which may lead to better overall care and quality of life for multiple myeloma patients undergoing these intensive treatments.

This study tests a combination of three cancer medicines (isatuximab, lenalidomide, and dexamethasone) using lower than standard doses for patients with newly diagnosed multiple myeloma who are frail or much older. The study aims to find out if using reduced doses can effectively treat multiple myeloma while causing fewer side effects in patients who may not be strong enough for full-intensity treatment.

This study examines belantamab mafodotin, a targeted cancer treatment, in patients with relapsed or refractory multiple myeloma who have normal liver function compared to those with liver problems. The research aims to determine how liver impairment affects the way the body processes this medication, which could help doctors better customize dosing and improve treatment safety for multiple myeloma patients with varying liver function.

This study tests a combination treatment of dasatinib and quercetin along with CAR-T cell therapy for patients with multiple myeloma that has returned or stopped responding to previous treatments. The unique approach combines targeted drugs that may help cancer cells die with an advanced immunotherapy that uses the patient's own immune cells, potentially offering a more effective treatment option for patients who have already tried at least three different therapies.

This study is testing whether advanced genetic testing can help doctors determine when it's safe to delay stem cell transplant in patients with newly diagnosed multiple myeloma. The research uses a technique called minimal residual disease testing to personalize treatment timing, which could allow some patients to avoid or postpone transplant while maintaining good outcomes.

This study tests a combination of four medications (daratumumab, carfilzomib, pomalidomide, and dexamethasone) for patients with multiple myeloma that has returned or stopped responding to previous treatments. The study is unique because it combines two investigational drugs with two standard treatments to potentially offer a new treatment option for patients whose cancer has become resistant to earlier therapies.

This study is testing a combination of four cancer drugs (isatuximab, pomalidomide, elotuzumab, and dexamethasone) in patients with multiple myeloma that has returned or stopped responding to at least two previous treatments. This research combines multiple targeted therapies in a single treatment approach, which may offer better disease control and potentially improved outcomes for patients whose cancer has become resistant to standard treatments.

This study tests CS1-CAR T therapy (genetically modified immune cells) in patients with multiple myeloma that has returned or stopped responding to at least three previous standard treatments. The treatment uses the patient's own immune cells that are engineered to specifically recognize and attack CS1-positive multiple myeloma cells, offering a personalized approach that may provide new hope for patients with hard-to-treat disease.

This study is testing APG-2575, an experimental oral medication, in patients with blood cancers including multiple myeloma who have not responded to or cannot receive standard treatments. The research aims to determine the safest and most effective dose of this new drug, which works differently from current therapies and may offer hope for patients with treatment-resistant blood cancers.

This study compares different pain control methods for patients with multiple myeloma, lymphoma, or bone metastases who are having preventive surgery to place metal rods in their thigh bones before fractures occur. This research is unique because it tests whether combining toradol (a non-opioid pain medication) with opioids provides better pain relief than using opioids alone, potentially reducing the need for narcotic medications after surgery.

This study is testing iberdomide, either alone or combined with dexamethasone, to treat people with intermediate- or high-risk smoldering multiple myeloma (an early stage of blood cancer that has not yet caused symptoms). The treatment works by boosting the immune system to help fight cancer cells and may prevent or delay the progression to active multiple myeloma while being better tolerated than other treatments.

This study tests the combination of ATRA (a vitamin A-related drug) and carfilzomib in patients with multiple myeloma whose cancer has not responded to at least three previous treatments, including proteasome inhibitors. This research is unique because it explores whether ATRA can make multiple myeloma cells more sensitive to carfilzomib treatment, potentially offering new hope for patients with hard-to-treat cancer.

This study examines ide-cel (bb2121), a CAR T-cell immunotherapy treatment, for multiple myeloma patients who have previously received a stem cell transplant and have tried at least four other treatment approaches. The research focuses on whether the quality of T-cells used to create the therapy affects how well ide-cel prevents cancer from returning, potentially offering new insights to improve treatment outcomes for patients with relapsed or treatment-resistant multiple myeloma.

This study tests whether an interactive website called Mosaic helps adult patients with blood cancers, including multiple myeloma, who are receiving stem cell transplants, compared to patients using a standard educational website. The Mosaic website may help multiple myeloma patients better manage stress, physical symptoms, and overall quality of life during their transplant journey by improving their preparation and coping skills.

This study is testing a new type of PET scan using a special tracer called 89Zr-DFO-daratumumab to better detect and monitor multiple myeloma cancer cells in patients with this blood cancer. This advanced imaging technique targets a specific protein (CD38) found on myeloma cells, which could help doctors more accurately see where the cancer is located in the body and better plan treatments or check how well treatments are working.

This study is testing a new experimental treatment called ISB 2001 in patients with relapsed or refractory multiple myeloma (cancer that has returned or stopped responding to previous treatments). This is the first time ISB 2001 has been tested in humans, which could provide a new treatment option for multiple myeloma patients whose cancer has not responded to standard therapies.

This study tests a combination treatment called radioimmunotherapy (using radioactive substances attached to daratumumab antibody) for patients with multiple myeloma that has returned or stopped responding to previous treatments. This approach is unique because it delivers targeted radiation directly to cancer cells while also using the immune system to fight the disease, potentially offering a new treatment option for patients whose cancer has become resistant to standard therapies.

This study tests a new drug combination called Dara-SVD (which includes selinexor, daratumumab, velcade, and dexamethasone) compared to the standard treatment Dara-RVD for patients with newly diagnosed high-risk multiple myeloma. The study is unique because it uses selinexor in the initial treatment instead of waiting until the cancer returns, which may provide better outcomes for patients with high-risk forms of multiple myeloma.

This study is testing a new CAR-T cell therapy called WS-CART-CS1 in patients with multiple myeloma whose cancer has returned or stopped responding to treatment after receiving at least three prior therapies. This treatment targets a protein called CS1 that is found on most multiple myeloma cells, potentially offering a new treatment option for patients who have exhausted other therapies including proteasome inhibitors, anti-CD38 treatments, and BCMA-targeted therapies.

This study is testing talquetamab, a targeted therapy, for people with multiple myeloma who have already received BCMA CAR T-cell therapy. This research is unique because it specifically focuses on patients who have completed CAR T-cell treatment and aims to determine if talquetamab can provide effective follow-up treatment to help maintain or improve their response to therapy.

This study is testing a combination treatment of isatuximab, carfilzomib, and dexamethasone for adults with multiple myeloma that has returned or stopped responding to previous treatments. What makes this study unique is that isatuximab is given as a weekly injection under the skin using a special delivery device, which may be more convenient for patients than traditional intravenous treatments and could provide an effective new treatment option for those who have received 1 to 3 prior therapies.

This study examines low-dose radiation therapy to treat bone pain in multiple myeloma patients whose cancer has spread to their bones. The low-dose approach may offer patients fewer side effects, greater convenience, and less interference with their chemotherapy schedule compared to standard radiation treatment.

This study tests a combination of iberdomide and daratumumab as maintenance therapy for multiple myeloma patients who have completed stem cell transplant but still have detectable cancer cells in their body. The research aims to determine if this two-drug combination can effectively eliminate remaining cancer cells and provide a safe treatment option to help prevent the cancer from returning.

This study examines whether specialized lighting treatments can help multiple myeloma patients who are receiving stem cell transplants by improving their body's natural sleep-wake cycles. The research is unique because it focuses on using light therapy to potentially reduce inflammation, fever from low white blood cell counts, and other symptoms that commonly affect patients during this intensive treatment period.

This study is testing linvoselumab, an experimental drug, combined with other cancer treatments for adults with multiple myeloma (a blood cancer) that has stopped responding to standard treatments. This is the first time linvoselumab will be combined with other cancer therapies, which may provide a new treatment option for patients whose multiple myeloma has become resistant to current standard treatments.

This study is testing the antiviral medication ibuzatrelvir, either alone or combined with remdesivir, compared to remdesivir alone for treating COVID-19 in adults with severely weakened immune systems who do not need oxygen support. This research is unique because it focuses specifically on immunocompromised patients, including those with multiple myeloma and other blood cancers, who may have difficulty clearing COVID-19 infections and could benefit from more effective antiviral treatments.

This study tests a combination of four medications (elotuzumab, daratumumab, iberdomide, and dexamethasone) for patients with multiple myeloma that has returned after previous treatments. The study is unique because it combines an investigational drug (iberdomide) with established therapies to potentially offer a new treatment option for patients whose cancer has relapsed despite receiving multiple prior therapies including proteasome inhibitors, immunomodulatory drugs, and anti-CD38 treatments.

This study is comparing cancer treatment given at home versus in a clinic for patients with advanced cancer, including Multiple Myeloma and many other cancer types. This research may help reduce the physical, emotional, and financial burden on Multiple Myeloma patients and their families by allowing them to receive their cancer treatments in the comfort of their own homes while maintaining the same quality of care.

This study is testing a new drug called Enzomenib (DSP-5336) in adults with acute leukemia (AML or ALL) that has returned or not responded to previous treatments. The study is unique because it focuses on patients with specific genetic changes in their cancer cells and tests Enzomenib both alone and in combination with other cancer drugs to find the most effective treatment approach.

This study follows patients with multiple myeloma and other blood cancers who previously received AUTO CAR T cell therapy, a treatment that uses the patient's own immune cells that have been genetically modified to better fight cancer. The study tracks patients for up to 15 years to monitor the long-term safety and effectiveness of this innovative treatment, providing valuable information about how well these modified immune cells work over time.

This study tests genetically modified immune cells called NK cells, taken from cord blood and engineered to target a specific protein, in patients with multiple myeloma that has returned or stopped responding to treatment. The treatment combines these modified NK cells with chemotherapy drugs to prepare the body, offering a potentially new approach for patients who have already tried multiple standard therapies including proteasome inhibitors and anti-CD38 antibodies.

This study tests JNJ-68284528, an experimental CAR-T cell therapy that uses genetically modified immune cells to target BCMA (a protein found on multiple myeloma cells), in patients with multiple myeloma at various stages of treatment. The treatment aims to achieve minimal residual disease-negative status, meaning no detectable cancer cells remain after treatment, which could potentially lead to longer-lasting remissions for multiple myeloma patients.

This study compares a new cancer drug called BMS-986393 against standard treatments for adults with multiple myeloma that has returned or stopped responding to treatment, particularly in patients who have previously received lenalidomide therapy. This research is important because it may provide a new treatment option for patients whose multiple myeloma is difficult to treat after trying multiple previous therapies.

This study provides continued access to elranatamab, a targeted cancer treatment, for multiple myeloma patients who previously participated in other elranatamab trials and are still benefiting from the medication. This post-trial access study ensures that patients who are responding well to elranatamab can continue receiving this treatment even after their original clinical trial has ended, potentially helping to maintain disease control and quality of life.

This study is testing talquetamab, a new cancer treatment, in patients with multiple myeloma (a blood cancer) that has returned or stopped responding to previous treatments. The research focuses on finding the right dose and evaluating how well this medication works in patients who have already tried other therapies, potentially offering a new treatment option for those with limited alternatives.

This study is testing a combination of bortezomib, pembrolizumab, and dexamethasone with or without pelareorep (a laboratory-modified virus) for patients with multiple myeloma that has returned or stopped responding to treatment after at least three previous therapies. This approach is unique because it combines traditional chemotherapy drugs with an immunotherapy drug and potentially a modified virus that may kill cancer cells without harming normal cells, offering a new treatment option for patients whose cancer has become resistant to standard therapies.

This study is testing a new treatment called REGN5458 (also known as Linvoseltamab) for adults with multiple myeloma that has returned or stopped responding to previous treatments. The treatment uses a unique approach that helps the body's immune system find and attack cancer cells, potentially offering hope for patients whose cancer has not responded to at least three previous therapies including standard multiple myeloma medications.

This study is testing a care coordination program between cancer pharmacists and community pharmacists to help patients with blood cancers like multiple myeloma who are starting oral cancer medications and have multiple other chronic health conditions. The unique approach uses coordinated pharmacist communication and comprehensive medication reviews to improve how patients manage both their cancer treatment and other medications, which may lead to better overall health outcomes for multiple myeloma patients with complex medical needs.

This study is testing STI-1492, a specially engineered immune cell therapy called CAR-T cells that target the CD38 protein, in patients with multiple myeloma that has returned or stopped responding to previous treatments. What makes this treatment unique is that it uses donor immune cells (allogeneic) rather than the patient's own cells, which could make the therapy more readily available and may provide stronger cancer-fighting abilities for multiple myeloma patients.

This study is testing whether combining Teclistamab or Talquetamab with Daratumumab can help patients with high-risk smoldering multiple myeloma (a precancerous condition that may develop into multiple myeloma). The goal is to determine if these drug combinations can delay or prevent the progression from smoldering myeloma to active multiple myeloma, potentially offering patients a way to stay healthier longer before needing more intensive cancer treatment.

This study is testing different combinations of targeted cancer medications, including talquetamab plus pomalidomide or teclistamab, compared to standard treatment combinations in patients with multiple myeloma that has returned or stopped responding to previous treatments. This research is specifically designed for patients who have already received anti-CD38 antibody therapy and lenalidomide, offering new treatment options that may help control their cancer when other therapies have failed.

This study tests non-drug treatments including exercise, nutrition changes, and a heart medication called propranolol in patients with multiple myeloma or related blood disorders. The research aims to find new ways to strengthen the immune system and improve daily life for patients by combining these supportive treatments with standard cancer care.

This study tests a combination treatment of iberdomide, daratumumab, bortezomib, and dexamethasone for patients with newly diagnosed multiple myeloma. This research aims to find the safest dose of iberdomide when combined with these other drugs and may offer patients a new treatment option that could be more effective at stopping cancer cell growth than current standard treatments.

This study is testing advanced imaging techniques (MRI and PET scans) in patients with primary amyloidosis, a disease where abnormal proteins build up in organs and can cause heart problems. The research aims to develop better ways to see amyloid protein deposits in the heart, which could help doctors understand how the heart becomes damaged and lead to new life-saving treatments for patients with this condition.

This study tests a combination of belantamab mafodotin (a targeted therapy that delivers chemotherapy directly to cancer cells) and lenalidomide in multiple myeloma patients who still have detectable cancer cells after stem cell transplant. The goal is to help patients achieve complete remission by eliminating remaining cancer cells that standard treatments may have missed.

This study is testing whether lower doses of cyclophosphamide chemotherapy combined with reduced duration of another immune-suppressing medication can help patients with blood cancers like multiple myeloma have safer bone marrow transplants from related donors. The research aims to reduce transplant complications and side effects while maintaining the treatment's effectiveness, potentially offering patients a less toxic path to successful transplantation.

This study compares two treatment approaches for patients with newly diagnosed multiple myeloma who have already received initial induction therapy: a T-cell engager medication called elranatamab combined with daratumumab versus the standard approach of autologous stem cell transplant followed by lenalidomide and daratumumab. The study uses advanced testing to measure minimal residual disease in bone marrow, helping doctors determine which treatment approach is more effective at achieving the deepest possible remission and potentially improving long-term outcomes for multiple myeloma patients.

This study is testing cevostamab, a new cancer treatment, in patients with relapsed or refractory multiple myeloma who have already received CAR T cell therapy. The unique approach involves giving cevostamab as a follow-up treatment starting about 10 weeks after CAR T cell therapy, which may help more patients achieve complete remission without detectable cancer cells.

This study is testing a new imaging agent called [68Ga]-pentixafor with PET/CT scans in patients who have blood cancers like multiple myeloma, non-Hodgkin lymphoma, or related blood disorders. This imaging method could help doctors better see and track these cancers in the body, potentially leading to more accurate diagnosis and treatment monitoring for multiple myeloma patients.

This study is testing a new imaging agent called 64Cu-LLP2A using PET/CT scans to better detect multiple myeloma and low-grade lymphomas in patients with these blood cancers. This imaging approach may help doctors see cancer cells more clearly than current methods, potentially leading to earlier detection of disease recurrence and better treatment planning for patients with blood cancers.

This study tests a combination of three drugs (mezigdomide, carfilzomib, and dexamethasone) for patients with multiple myeloma that has returned or stopped responding to treatment and has spread to soft tissues or organs outside the bone marrow. The treatment specifically targets this challenging form of multiple myeloma where cancer cells have formed tumors in areas beyond the bone marrow, potentially offering new hope for patients with this difficult-to-treat condition.

This study is testing different sequences of advanced immunotherapy treatments (including CAR-T cell therapy and targeted antibody drugs) combined with standard multiple myeloma medications for people newly diagnosed with standard-risk multiple myeloma. The study aims to find the best treatment sequence that could potentially lead to a functional cure, measured by having no detectable cancer cells for at least 2 years and clear scans after 5 years of treatment.

This study compares a combination chemotherapy treatment called Dara-VCD (daratumumab, cyclophosphamide, bortezomib, and dexamethasone) alone versus the same treatment followed by high-dose chemotherapy with stem cell transplant for people newly diagnosed with AL amyloidosis, a rare disease where abnormal proteins build up in organs. This research is unique because it directly tests whether adding a stem cell transplant after initial chemotherapy provides better long-term outcomes for AL amyloidosis patients compared to chemotherapy treatment alone.

This study examines whether multiple myeloma patients who have very good partial response or complete response after stem cell transplant can safely stop their maintenance therapy. The research aims to determine if patients with no detectable cancer remaining can maintain their remission without continuing long-term treatment, potentially reducing side effects and improving quality of life.

This study tests GC012F (AZD0120), a special immune cell therapy called CAR T-cell therapy that targets two proteins (CD19 and BCMA) on cancer cells, in patients with newly diagnosed or early relapsed/refractory multiple myeloma. This treatment is unique because it attacks cancer cells through two different targets at once, which may help prevent the cancer from developing resistance and could provide better outcomes for patients with high-risk or early-stage relapsed multiple myeloma.

This study is testing two new treatment combinations (teclistamab with daratumumab and lenalidomide, or talquetamab with daratumumab and lenalidomide) compared to a standard treatment for people with newly diagnosed multiple myeloma who cannot have a stem cell transplant. The study aims to determine if adding these newer targeted therapies to existing treatments can help patients live longer without their cancer getting worse.

This study is testing talquetamab, a new immunotherapy drug given as an injection under the skin, for elderly patients with multiple myeloma that has returned after previous treatments. The study is unique because it starts with talquetamab alone and adds daratumumab (another immunotherapy) if the cancer doesn't respond well, potentially offering an effective yet gentler treatment approach specifically designed for elderly patients who may not be candidates for more intensive therapies.

This study tests iberdomide combined with other cancer drugs (carfilzomib, daratumumab, and dexamethasone) in multiple myeloma patients who have undergone stem cell transplant but still have detectable cancer cells in their bone marrow. The goal is to eliminate these remaining cancer cells (called minimal residual disease) to potentially provide longer-lasting cancer control and improve outcomes for patients at high risk of relapse.

This study is testing selinexor, a new cancer drug, in combination with lenalidomide and methylprednisolone for patients with multiple myeloma that has not responded to previous lenalidomide-containing treatments. This research is unique because it offers a potential treatment option for patients whose cancer has become resistant to lenalidomide, which may help control their disease when standard therapies are no longer effective.

This study is testing whether time-restricted eating (eating all food within a 10-hour window each day) can help reduce severe fatigue in people who have been treated for blood cancers like leukemia, lymphoma, and multiple myeloma. This approach is unique because it focuses on when patients eat rather than what they eat, with the goal of resetting the body's internal clock that may have been disrupted by cancer treatment, potentially offering a new way to manage the exhausting fatigue that often persists long after treatment ends.

This study is testing elranatamab, a targeted therapy, in patients with multiple myeloma whose cancer has returned or stopped responding to previous treatments. Elranatamab works differently than standard treatments by helping the immune system recognize and attack cancer cells, potentially offering a new treatment option for patients who have already tried 1-3 other combination therapies.

This study is testing whether a shortened radiation treatment schedule (called hypofractionation) is safe and effective for people with multiple myeloma who need radiation therapy for their bone lesions. This approach uses higher daily radiation doses given over fewer days compared to the standard 2-3 week treatment schedule, which could make treatment more convenient for patients while maintaining the same cancer-fighting effectiveness.

This study compares stereotactic body radiation therapy (SBRT), a highly precise radiation treatment, with standard radiation therapy for patients who have cancer that has spread to their bones and is causing pain. SBRT delivers focused, high-dose radiation in fewer treatments, which may provide better pain relief and improved quality of life for patients with bone metastases from various cancers, including multiple myeloma.

This study is testing whether budesonide, a steroid medication, can reduce severe diarrhea in multiple myeloma patients receiving an autologous stem cell transplant (using their own stem cells). The research compares budesonide to a placebo to determine if this targeted approach can prevent a common and serious side effect that affects patients during this important cancer treatment.

This study is testing a new imaging agent called 18F-fluciclovine in PET/CT scans to detect multiple myeloma in adults with newly diagnosed or returning cancer. The research aims to determine if this new radiotracer can find multiple myeloma cells more effectively than the current standard imaging method, potentially leading to earlier detection of disease progression and better treatment planning for patients.

This study is testing the combination of elranatamab and iberdomide as a treatment for patients with multiple myeloma that has returned or stopped responding to previous treatments. The research aims to find the safest and most effective doses of these two medicines when used together, which could provide a new treatment option for patients whose cancer has become resistant to other therapies.

This study is testing CB-011, a new type of CAR-T cell therapy that uses specially modified immune cells from donors to target a protein called BCMA in patients with multiple myeloma that has returned or stopped responding to treatment. This treatment is unique because it uses donor cells that have been gene-edited with CRISPR technology, which may offer advantages over traditional CAR-T therapies by potentially being more readily available and effective against cancer cells.

This study is testing whether giving patients with high-risk blood cancers (including multiple myeloma) an infusion of white blood cells from their bone marrow transplant donor can help reduce the chance of cancer returning. This approach is unique because the donor's immune cells are given early after transplant to potentially strengthen the body's ability to fight any remaining cancer cells, which could lead to better long-term outcomes for multiple myeloma patients.

This study is testing an educational video and materials to help adults with serious cancer diagnoses better understand and use palliative care services. The study is unique because it focuses on improving patients' knowledge about palliative care through multimedia education, which may help patients feel better emotionally and physically while making more informed decisions about their care.

This study compares two maintenance treatment approaches for multiple myeloma patients after stem cell transplant: lenalidomide alone versus lenalidomide combined with daratumumab/rHuPH20. The study uses a unique approach where treatment duration is guided by minimal residual disease (MRD) testing, allowing doctors to personalize how long patients continue therapy based on whether cancer cells can still be detected in their body.

This study is testing a combination of four drugs (bortezomib, isatuximab, cyclophosphamide, and dexamethasone) as initial treatment for patients with multiple myeloma who have kidney problems and are eligible for stem cell transplant. This research is unique because it specifically focuses on how this four-drug combination works in multiple myeloma patients with reduced kidney function, which could lead to better treatment options for this particular group of patients who often face more complex treatment challenges.

This study is testing a treatment called cytokine-treated veto cells in patients with blood cancers (like multiple myeloma, leukemia, and lymphoma) who are receiving stem cell transplants from partially matched family donors. The special veto cells may help the transplanted donor cells grow and develop properly while reducing the risk of graft-versus-host disease, a serious complication where the donor cells attack the patient's healthy tissues.

This study is testing an experimental drug called linvoseltemab in adults who have been recently diagnosed with multiple myeloma but have not yet received treatment. This research offers a "window of opportunity" to evaluate whether linvoseltemab can safely shrink tumors before patients begin standard treatments, potentially providing valuable information about a new treatment option for newly diagnosed multiple myeloma patients.

This study tests personalized natural killer (NK) cell therapy in patients with blood cancers including multiple myeloma, leukemia, lymphoma, and myelodysplastic syndrome who are receiving chemotherapy followed by umbilical cord blood transplant. The treatment uses specially selected cord blood based on genetic matching and adds NK immune cells that may destroy remaining cancer cells after chemotherapy while reducing the risk of transplant complications.

This study tests whether prebiotic supplements (resistant starch) can improve gut bacteria diversity in patients with multiple myeloma or lymphoma who are receiving an autologous stem cell transplant. The research is unique because it focuses on supporting gut health during transplant recovery, which may lead to better survival outcomes since healthier gut bacteria has been linked to improved results after stem cell transplantation.

This study is testing the combination of two cancer medicines, teclistan and meziglomide, in people with multiple myeloma that has returned or stopped responding to previous treatments. This research is unique because it combines these two drugs to potentially provide a new treatment option for patients whose cancer has not responded to standard therapies including proteasome inhibitors, immunomodulatory drugs, and anti-CD38 antibodies.

This study is testing a physical activity program called CHAMPS-II to help improve thinking and memory problems in adults age 55 and older who have blood cancers like multiple myeloma and are receiving stem cell transplants. The research is unique because it specifically focuses on how exercise might protect brain function during cancer treatment, and it studies the connection between aging-related brain changes and cancer treatment effects on thinking abilities.

This study is testing cemsidomide (CFT7455), a new oral medication, in patients with relapsed or refractory Multiple Myeloma and Non-Hodgkin's lymphoma who have not responded to previous treatments. The research aims to determine the safest and most effective dose of cemsidomide, which may offer a new treatment option for patients whose cancer has returned or stopped responding to standard therapies.

This study tests whether a home-based mindfulness and physical activity program combined with telephone health coaching can reduce fatigue and improve quality of life in older patients with multiple myeloma who are currently receiving maintenance treatment. The program uniquely combines gentle, holistic activities that can be done at home with remote monitoring technology and personalized coaching support, which may help address the high symptom burden that multiple myeloma patients experience compared to other blood cancers.

This study is testing teclistamab, a targeted therapy, for patients with multiple myeloma that has returned or stopped responding to previous treatments including proteasome inhibitors, immunomodulatory drugs, and anti-CD38 antibodies. The trial uses an adaptive platform design that allows researchers to efficiently test multiple treatments within one study framework, potentially helping doctors identify the best treatment options for individual patients more quickly.

This study tests LMY-920, a new type of CAR-T cell therapy that uses the patient's own immune cells modified with BAFF-ligand, for people with multiple myeloma that has returned or stopped responding to at least three previous treatments. This approach offers a potential new treatment option for patients whose myeloma has become resistant to standard therapies, including those who may have already tried other CAR-T cell treatments.

This study compares a three-drug combination treatment (mezigdomide, carfilzomib, and dexamethasone) against a two-drug combination (carfilzomib and dexamethasone) in patients with relapsed or refractory multiple myeloma who have received at least one prior treatment. The addition of mezigdomide, a new targeted therapy, to the standard two-drug combination may help improve treatment outcomes for multiple myeloma patients whose cancer has returned or stopped responding to previous treatments.

This study examines umbilical cord blood transplantation from unrelated donors as a treatment for patients with blood cancers including Multiple Myeloma, leukemia, lymphoma, and other blood disorders who need stem cell transplants. This approach may benefit Multiple Myeloma patients by providing access to stem cell transplantation when a closely matched related or unrelated donor is not available within the needed timeframe, potentially offering a life-saving treatment option using cord blood as an alternative donor source.

This study provides continued access to daratumumab treatment for patients with multiple myeloma or smoldering multiple myeloma who are currently benefiting from this medication in previous clinical trials. The study is unique because it allows patients to keep receiving effective treatment even after their original trial ends, potentially extending the benefits they are experiencing from daratumumab-based therapy.

This study is testing belantamab, a cancer drug, both alone and combined with belantamab mafodotin for patients with multiple myeloma that has stopped responding to at least three previous treatments. The research is unique because it explores using belantamab as a single treatment and in combination therapy, which may provide new treatment options for patients whose cancer has become resistant to standard therapies.

This study tests a combination treatment using specially modified immune cells from donors (called TiNK cells) along with the drug isatuximab for patients with multiple myeloma that has returned after treatment or has not responded to previous therapies. The unique approach combines these laboratory-enhanced natural killer cells with standard medications to potentially provide a more effective treatment option for patients whose cancer has been difficult to control with existing therapies.

This study is testing HDP-101, an experimental treatment, in patients with multiple myeloma that has returned or stopped responding to previous treatments. The study focuses on evaluating the safety and potential effectiveness of this new therapy, which may offer hope for patients who have already tried multiple standard treatments including stem cell transplant or other established cancer drugs.

This study is testing a combination of three medications - Selinexor, Ruxolitinib, and Methylprednisolone - for patients with multiple myeloma that has come back or stopped responding to treatment after at least three previous therapies. This unique three-drug combination targets cancer cells through different pathways and may offer new hope for multiple myeloma patients who have exhausted standard treatment options.

This study is testing a new imaging scan called [89Zr]DFO-YS5 PET to detect multiple myeloma cancer cells that have a specific protein called CD46. The scan uses a special radioactive tracer that targets CD46-positive cancer cells, which may help doctors better detect and locate multiple myeloma throughout the body compared to current imaging methods.

This study tests a combination of ruxolitinib (a JAK inhibitor), steroids, and lenalidomide in multiple myeloma patients whose disease has progressed after receiving at least two previous treatments. The study uniquely uses changes in blood levels of a protein called BCMA to help determine if the cancer is getting worse, which may provide a better way to monitor disease progression in multiple myeloma patients.

This study is testing a combination treatment called Dara-CyBorD (daratumumab with cyclophosphamide, bortezomib, and dexamethasone) for newly diagnosed multiple myeloma patients who also have kidney failure. This research is unique because it specifically focuses on how well this treatment works for patients with both multiple myeloma and kidney problems, and it will compare treatment responses between African American and non-African American patients.

This study is testing IgPro20, an antibody replacement therapy, in multiple myeloma patients who have developed low antibody levels (hypogammaglobulinemia) as a side effect of their cancer treatment with bispecific antibodies. The research aims to determine if IgPro20 can help prevent serious infections in these patients by boosting their weakened immune systems.

This study is testing TriPRIL CAR T cells, a new type of immunotherapy that uses modified immune cells, in people with multiple myeloma that has returned or stopped responding to treatment. The treatment is unique because it targets three different proteins on cancer cells at once, which may help overcome resistance and provide better results for patients whose cancer has not responded to standard treatments including proteasome inhibitors, immunomodulatory drugs, and anti-CD38 antibodies.

This study compares elranatamab (given as an injection under the skin) to lenalidomide (taken as a pill) as maintenance treatment for patients with newly diagnosed multiple myeloma who have already received a stem cell transplant. The study is unique because it tests whether elranatamab, a newer targeted therapy that helps the immune system fight cancer cells, can provide better long-term control of multiple myeloma compared to the standard maintenance treatment.

This study compares lenalidomide and dexamethasone treatment with or without daratumumab for patients with high-risk smoldering multiple myeloma, a condition where abnormal plasma cells exist in the bone marrow but haven't yet caused symptoms. The research aims to determine whether adding daratumumab to the standard two-drug combination can better prevent the disease from progressing to active multiple myeloma and improve patient outcomes.

This study examines CAR T-cell therapy, an advanced cancer treatment that uses genetically modified immune cells, in patients with multiple myeloma, certain lymphomas, or leukemia who also have moderate to severe kidney problems. The research is unique because it tests whether adjusting the doses of pre-treatment chemotherapy drugs makes CAR T-cell therapy safer and more feasible for patients with kidney dysfunction, potentially expanding treatment options for this underserved patient population.

This study is testing belantamab mafodotin, a targeted drug therapy, in multiple myeloma patients who are receiving stem cell transplant treatment. The study is unique because it combines this investigational drug with standard transplant procedures and maintenance therapy to potentially improve treatment outcomes for patients with this blood cancer.

This study tests a combination treatment of belantamab mafodotin with carfilzomib, pomalidomide, and dexamethasone for patients with multiple myeloma that has returned and is not responding to standard treatments, including CAR-T cell therapy. This unique four-drug combination offers a new treatment option for patients with hard-to-treat multiple myeloma by combining different types of cancer-fighting medicines that work together to attack the cancer cells.

This study tests whether a combination of belantamab mafodotin and lenalidomide, given as maintenance therapy after stem cell transplant, can help patients with newly diagnosed multiple myeloma achieve undetectable levels of remaining cancer cells. The treatment approach is personalized based on minimal residual disease testing, which may help doctors better eliminate any remaining cancer cells and potentially improve long-term outcomes for multiple myeloma patients.

This study is testing a treatment called cilta-cel (CAR-T cell therapy) combined with chemotherapy drugs for patients with high-risk smoldering multiple myeloma, a condition where cancer cells are present but not yet causing symptoms. This research is unique because it aims to prevent smoldering multiple myeloma from progressing to active cancer by using an advanced immunotherapy that trains the patient's own immune cells to fight the cancer cells before symptoms develop.

This study compares iberdomide maintenance therapy to standard monitoring for multiple myeloma patients who have already received CAR-T cell therapy with idecabtagene vicleucel. This research may help patients maintain cancer control for longer periods by using iberdomide to enhance the immune system and potentially extend the effectiveness of their previous CAR-T treatment.

This study is testing a comprehensive assessment tool called IA3-CP that evaluates aging-related health factors, mental health, and social needs in older adults (65 and over) with various blood cancers and solid tumors, including Multiple Myeloma. The assessment system is designed to help doctors create more personalized treatment plans by identifying specific support needs and health concerns that could affect cancer care decisions and outcomes.

This study is testing a new drug called JNJ-79635322 in patients with multiple myeloma that has returned or stopped responding to treatment, and in patients with AL amyloidosis who have been previously treated. The research aims to find the safest and most effective dose of this experimental medicine and may offer a new treatment option for patients whose cancer has not responded to standard therapies including proteasome inhibitors, immunomodulatory drugs, and anti-CD38 treatments.

This study compares adding radiation therapy to standard care versus standard care alone for cancer patients who have high-risk bone metastases (cancer that has spread to bones) that are not currently causing symptoms. The study aims to determine if preventive radiation therapy can better reduce bone-related complications like fractures or spinal cord compression compared to waiting and watching, potentially helping patients avoid serious problems before they develop symptoms.

This study tests a personalized T-cell therapy for patients with advanced Multiple Myeloma and other cancers that have spread and not responded to standard treatments. The treatment involves removing a patient's immune cells, genetically modifying them in a laboratory to better recognize and attack their specific tumor mutations, then infusing these enhanced cells back into the patient to potentially shrink tumors.

This study examines daratumumab maintenance therapy for patients with light chain amyloidosis who have already completed initial treatment and achieved a good response. The research compares different durations of maintenance treatment to determine the optimal length of therapy needed to keep the disease from returning and improve long-term survival outcomes.

This study is testing SIM0500, an experimental treatment given alone, in adults with relapsed or refractory multiple myeloma who have not responded to standard treatments. The research uses a unique two-part approach to find the safest and most effective dose, which may provide a new treatment option for multiple myeloma patients whose cancer has returned or stopped responding to other therapies.

This study is testing QXL138AM, a new experimental treatment given through IV infusion every two weeks, in patients with advanced solid tumors (including prostate, lung, breast, ovarian, and other cancers) and multiple myeloma who have not responded to standard treatments. This is the first study of QXL138AM in humans, combining a targeted antibody with interferon to potentially offer a new treatment option for Multiple Myeloma patients who have tried at least three previous therapies including proteasome inhibitors, immunomodulatory drugs, and anti-CD38 treatments.

This study is testing a combination of two medications, venetoclax and tocilizumab, to treat patients with a specific type of multiple myeloma called t(11;14) that has returned or stopped responding to previous treatments. This research is unique because it combines venetoclax, which blocks a protein that helps cancer cells survive, with tocilizumab, which may help control side effects from cancer treatment, potentially offering a new treatment approach for patients with this challenging form of multiple myeloma.

This study is testing high-dose vitamin C (ascorbic acid) combined with a reduced dose of the chemotherapy drug melphalan before stem cell transplant in patients with multiple myeloma that has returned or stopped responding to treatment. The research aims to determine if this combination approach can maintain treatment effectiveness while potentially reducing side effects compared to standard higher-dose chemotherapy regimens.

This study examines whether isatuximab, an antibody treatment, can improve immune system recovery in patients with multiple myeloma and lymphoma who are receiving stem cell transplants. The research aims to determine if isatuximab helps the immune system better fight cancer cells after transplant recovery, potentially offering a new way to enhance treatment outcomes for blood cancer patients.

This study is testing belumosudil mesylate, either alone or combined with dexamethasone, in patients with multiple myeloma that has returned or stopped responding to previous treatments. This research focuses on patients whose cancer has become resistant to three major drug classes (proteasome inhibitors, immunomodulatory drugs, and anti-CD38 antibodies), offering a potential new treatment option for those with limited therapeutic choices.

This study tests a combination of four cancer drugs (carfilzomib, daratumumab, lenalidomide, and dexamethasone) for patients with newly diagnosed high-risk multiple myeloma who have not yet received treatment. The study is unique because it focuses specifically on high-risk patients and aims to determine if this four-drug combination can improve blood test results and help patients achieve minimal residual disease, which means having very little cancer remaining after treatment.

This study is testing a new PET scan imaging agent called [18F]florbetaben to help diagnose cardiac AL amyloidosis, a serious heart condition where abnormal proteins build up in heart tissue. This imaging approach could provide doctors with a better, non-invasive way to detect this type of amyloidosis in the heart, potentially leading to earlier diagnosis and treatment for patients with this rare but serious condition.

This study compares etentamig, an investigational drug given through an IV, to standard available treatments in adults with multiple myeloma that has returned after treatment or has not responded to previous therapies. The study is unique because it tests etentamig as a single treatment (monotherapy) rather than in combination with other drugs, which may offer a simpler treatment approach for patients whose cancer has become resistant to multiple prior treatments including proteasome inhibitors, immunomodulatory drugs, and anti-CD38 antibodies.

This study is testing a new drug called BMS-986393 combined with other cancer medications (alnutuzumab, mezigdomide, and iberdomide) in patients with multiple myeloma that has returned or stopped responding to previous treatments. The research aims to find safe and effective drug combinations that could provide new treatment options for patients whose cancer has become resistant to standard therapies.

This study is testing SAR446523, a new injectable treatment given under the skin, for adults with multiple myeloma that has returned or stopped responding to previous treatments. The study is unique because it tests different dosing schedules to find the safest and most effective way to give this experimental medicine, which could provide a new treatment option for patients whose cancer has not responded to at least three previous therapies.

This study is testing a new treatment called TAA-specific CTLs (specially trained immune cells) for patients with multiple myeloma or pre-cancerous conditions that may develop into multiple myeloma. This treatment uses the patient's own immune system cells that are modified in the laboratory to better recognize and attack five specific proteins found on cancer cells, potentially helping to slow or stop disease progression.

This study is testing a digital health coaching program that includes weekly phone calls, educational materials, and wearable activity trackers for adults with relapsed or refractory multiple myeloma (cancer that has returned or stopped responding to treatment). This unique approach combines personal coaching support with wearable technology to better understand how patients experience their symptoms and treatment, potentially leading to improved quality of life and confidence in managing their condition.

This study is testing a new CAR-T cell therapy called OriCAR-017 in patients with relapsed or refractory multiple myeloma who have already received at least three previous treatments. What makes this treatment unique is that it targets a different protein called GPRC5D on cancer cells, offering a potential new option for patients whose cancer has stopped responding to other therapies including existing CAR-T treatments.

This study tests a new continuous under-the-skin infusion form of lenalidomide (STAR-LLD) combined with dexamethasone and a proteasome inhibitor for patients with multiple myeloma who need second-line or later treatment. The continuous infusion delivery method may help reduce side effects while maintaining effectiveness, potentially offering a better treatment experience for multiple myeloma patients compared to traditional oral lenalidomide.

This study is testing whether linvoselitamab can eliminate abnormal plasma cells in adults with high-risk MGUS (monoclonal gammopathy of undetermined significance) or non-high-risk smoldering multiple myeloma, which are conditions that may develop into multiple myeloma. This research is unique because it aims to prevent progression to active multiple myeloma by treating patients in earlier disease stages, potentially stopping the cancer before it fully develops and causes symptoms.

This study is testing sonrotoclax, a new cancer drug, either alone or combined with other medications (dexamethasone, carfilzomib, daratumumab, or pomalidomide) in patients with multiple myeloma that has returned or stopped responding to treatment and has a specific genetic change called t(11;14). This research focuses on patients with a particular genetic marker that may make them more likely to respond to sonrotoclax, potentially offering a targeted treatment option for this specific group of multiple myeloma patients.

This study tests whether using a lower dose of the drug cyclophosphamide after bone marrow transplant can reduce side effects while still preventing graft-versus-host disease in patients aged 60-85 or younger patients who cannot tolerate standard high-dose treatments for blood cancers like multiple myeloma. The research aims to find a safer transplant approach that maintains effectiveness while causing fewer complications, potentially making this life-saving treatment available to more patients who are currently considered too old or frail for standard procedures.

This study is testing selinexor combined with different standard multiple myeloma treatments for patients with both newly diagnosed and relapsed/refractory multiple myeloma. The study evaluates eleven different treatment combinations to determine the safest and most effective doses, offering patients access to innovative combination therapies that may improve treatment outcomes.

This study tests CLN-619, an antibody treatment that targets specific proteins (MICA/MICB) on cancer cells, in patients with multiple myeloma that has returned or stopped responding to previous treatments. The treatment works by helping the immune system recognize and attack myeloma cells more effectively, which may offer a new treatment option for patients whose cancer has become resistant to standard therapies.

This study is testing whether itacitinib, a drug that reduces inflammation and immune system activity, can be safely combined with a "mini" stem cell transplant using cells from a relative for older patients with blood cancers including multiple myeloma. The research aims to prevent serious side effects like cytokine release syndrome and potentially reduce the need for other immune-suppressing medications after transplant, which could improve outcomes for patients who are too old for standard intensive transplant procedures.

This study is testing a combination of three medicines - talquetamab, iberdomide, and dexamethasone - for patients with multiple myeloma that has returned after treatment or has not responded to previous therapies. This treatment combination offers a new approach that brings immune cells to attack myeloma cells while also targeting proteins that help cancer cells survive, which may provide hope for patients who have limited treatment options.

This study compares two different doses of olanzapine (2.5 mg versus 5 mg) combined with standard anti-nausea medications to prevent nausea and vomiting in multiple myeloma patients receiving high-dose melphalan chemotherapy before stem cell transplant. The research aims to find the most effective dose that controls nausea and vomiting while causing the least amount of drowsiness, potentially improving patients' comfort and quality of life during this intensive treatment.

This study compares two treatment combinations for adults with newly diagnosed multiple myeloma: a four-drug combination (daratumumab, bortezomib, lenalidomide, and dexamethasone) versus a three-drug combination (daratumumab, lenalidomide, and dexamethasone). The study aims to determine if adding bortezomib to the three-drug combination may be more effective at shrinking cancer or preventing it from returning in patients with standard-risk multiple myeloma.

This study examines the use of wearable sensors and advanced blood testing to monitor patients with blood cancers (including multiple myeloma, leukemia, and lymphomas) who are receiving CAR-T cell therapy. This research could lead to better early detection and management of serious side effects like cytokine release syndrome and brain-related complications, potentially making CAR-T treatment safer and more effective for multiple myeloma patients.

This study is testing ABBV-383, an experimental intravenous treatment, in adults with multiple myeloma that has returned or stopped responding to previous treatments. The study is unique because it tests different dosing strategies and explores outpatient administration of this new drug, which may offer patients more convenient treatment options while evaluating its safety and effectiveness.

This study is testing ABBV-383, an investigational drug given by injection under the skin and through IV infusion, for adults with multiple myeloma that has returned or stopped responding to previous treatments. The study is unique because it tests different ways of giving this new drug to find the safest and most effective approach for patients who have already tried 3-5 other treatments, potentially offering a new option when other therapies have failed.

This study compares two maintenance treatments, iberdomide and lenalidomide, for patients with newly diagnosed multiple myeloma who have already received an autologous stem cell transplant (a treatment using the patient's own stem cells). This research is unique because it directly compares these two oral medications to determine which one is more effective at keeping multiple myeloma from returning after transplant, potentially helping patients live longer without their cancer progressing.

This study tests a new drug called Belantamab Mafodotin in patients with high-risk smoldering multiple myeloma, a condition where abnormal plasma cells are present but have not yet caused symptoms. The treatment uses a targeted therapy that may help prevent the disease from progressing to active multiple myeloma, potentially delaying the need for more intensive treatments.

This study is testing a combination treatment of ruxolitinib, steroids, and lenalidomide for patients with multiple myeloma whose cancer has returned or stopped responding to previous treatments. This research is unique because it combines ruxolitinib (a drug that targets specific proteins involved in cancer growth) with established multiple myeloma medications, potentially offering a new treatment option for patients who have already tried at least two other treatment approaches including specific types of cancer drugs.

This study tests the safety and best dosing of venetoclax combined with other multiple myeloma treatments (lenalidomide, dexamethasone, and/or daratumumab) in patients with multiple myeloma who have a specific genetic marker called t(11;14). The research aims to find better treatment combinations that may provide improved cancer control compared to current standard treatments by adding venetoclax, a drug that blocks proteins cancer cells need to survive.

This study is testing etentamig, an investigational drug, combined with standard cancer treatments for adults with multiple myeloma that has returned or stopped responding to previous treatments. This research is unique because it explores adding etentamig to three different established treatment combinations to find the safest and most effective dose, potentially offering a new treatment option for patients whose cancer has become resistant to other therapies.

This study compares melphalan chemotherapy alone versus melphalan combined with siltuximab (an immune system drug) in multiple myeloma patients aged 60 and older who are receiving an autologous stem cell transplant. The research aims to determine if adding siltuximab can work as well as standard treatment while potentially reducing transplant-related side effects and improving patient outcomes.

This study is testing APG-2575 combined with standard multiple myeloma treatments (pomalidomide with dexamethasone, or daratumumab with lenalidomide and dexamethasone) in patients whose multiple myeloma has returned or stopped responding to previous treatments. The study is unique because it combines APG-2575, a new type of cancer drug that targets specific proteins in cancer cells, with proven multiple myeloma therapies to potentially improve treatment outcomes for patients who have limited remaining treatment options.

This study examines a personalized dosing approach for melphalan, a chemotherapy drug used before stem cell transplant in patients with multiple myeloma. The study uses blood level analysis to customize each patient's melphalan dose, which may help doctors determine the most effective and safest dose for each individual patient.

This study compares two treatment combinations for patients with multiple myeloma that has returned or stopped responding to previous treatments: one group receives selinexor, pomalidomide, and dexamethasone (SPd), while the other receives elotuzumab, pomalidomide, and dexamethasone (EloPd). The study is unique because it specifically includes patients who have already been treated with 1-4 previous therapies, including immunomodulatory drugs, proteasome inhibitors, and anti-CD38 antibodies, potentially offering new hope for those with limited remaining treatment options.

This study tests different doses and schedules of belantamab mafodotin, a targeted therapy that delivers chemotherapy directly to cancer cells, for patients with multiple myeloma that has returned or stopped responding to at least three previous treatments including specific drug classes. Researchers are investigating whether alternative dosing approaches can reduce eye-related side effects while maintaining effectiveness against this difficult-to-treat form of multiple myeloma.

This study tests whether Linvoselzumab, an immunotherapy drug, can help patients with newly diagnosed multiple myeloma who still have small amounts of cancer remaining after their initial treatment. The goal is to determine if this treatment can eliminate these remaining cancer cells and help patients stay in remission longer than with standard care alone.

This study tests an experimental virus-based vaccine called VSV-hIFNβ2-NIS, given alone or combined with chemotherapy and immunotherapy drugs, in patients with blood cancers like multiple myeloma, acute myeloid leukemia, or lymphoma that have returned or stopped responding to treatment. The vaccine uses a modified virus that preferentially infects and destroys cancer cells while protecting healthy cells, potentially offering a new treatment approach for patients with limited options.

This study examines the combination of isatuximab and lenalidomide as maintenance therapy for high-risk multiple myeloma patients who have received a stem cell transplant. The research aims to determine if this two-drug combination can better control high-risk multiple myeloma and prevent the cancer from returning after transplant compared to standard maintenance treatments.

This study is testing how well the Shingrix vaccine works to prevent shingles in patients who have received stem cell transplants from donors to treat blood cancers like multiple myeloma. The research will help doctors understand if this vaccine can effectively protect transplant patients, who have weakened immune systems and are at higher risk for developing shingles infections.

This study is testing CC-92480 (BMS-986348) combined with other cancer medications in patients with multiple myeloma that has returned or stopped responding to previous treatments. The research explores new drug combinations that may offer better treatment options for patients whose cancer has become resistant to standard therapies, including advanced treatments like CAR-T cell therapy.

This study is testing whether Alpha-1 Antitrypsin (AAT) can prevent graft-versus-host disease in patients with blood cancers like multiple myeloma who are receiving stem cell transplants from donors. The research compares AAT to a placebo to determine if this treatment can reduce the serious complication where transplanted cells attack the patient's healthy tissues, potentially making stem cell transplants safer and more successful.

This study is testing an inhaled experimental drug called PUL-042 in patients with blood cancers (including multiple myeloma) or stem cell transplant recipients who have developed lung infections from specific respiratory viruses (PIV, hMPV, or RSV). What makes this study unique is that it specifically targets immunocompromised cancer patients who are at high risk for severe viral lung infections, and the treatment is delivered directly to the lungs through inhalation, which may help reduce the severity of these potentially life-threatening respiratory infections.

This study is testing two different maintenance treatments - teclistamab combined with lenalidomide and teclistamab alone - compared to lenalidomide alone in people with newly diagnosed multiple myeloma who have already received a stem cell transplant. This research is unique because it examines whether adding teclistamab, a newer targeted therapy, to standard maintenance treatment can help keep multiple myeloma from returning longer than current treatments alone.

This study examines whether an 8-week virtual exercise program combining aerobic and strength training can help multiple myeloma patients prepare for stem cell transplant. The home-based exercise training may improve patients' physical strength, fitness, and overall health before their transplant procedure, potentially leading to better outcomes.

This study compares elranatamab, a new targeted therapy given as a weekly injection under the skin, to standard combination treatments in adults with multiple myeloma that has returned or stopped responding to previous treatments (including anti-CD38 antibody therapy and lenalidomide). This research is unique because it tests whether a single targeted drug can work as well as or better than multi-drug combinations, potentially offering multiple myeloma patients a simpler treatment option with fewer side effects.

This study is testing a new cell therapy called anitocabtagen autoleucel compared to standard treatments for people with multiple myeloma that has returned or stopped responding to previous treatments. This treatment uses the patient's own immune cells that are genetically modified to better fight the cancer, offering a potentially more targeted approach than current standard therapies for patients who have tried 1 to 3 previous treatment combinations.

This study tests the combination of targeted radiation therapy and talquetamab (an immunotherapy drug) for multiple myeloma patients whose cancer has spread to soft tissues outside the bone marrow (called extramedullary disease). This approach is unique because it combines precise radiation treatment directed at cancer sites outside the bone with a targeted therapy that helps the immune system fight myeloma cells, potentially offering a new treatment option for patients with this challenging form of the disease.

This study examines the safety of combining Cilta-cel (a personalized cell therapy made from the patient's own immune cells) with Talquetamab (a targeted therapy drug) for patients with high-risk multiple myeloma who have received at least three previous treatments. This combination approach is unique because it uses two different methods to attack cancer cells - reprogrammed immune cells and a targeted drug - which may provide better outcomes for patients whose multiple myeloma has not responded to standard treatments.

This study tests whether XEMBIFY (an antibody replacement therapy) combined with standard medical treatment can prevent serious bacterial infections in patients with Multiple Myeloma, chronic lymphocytic leukemia, or non-Hodgkin lymphoma who have low antibody levels and a history of severe or frequent infections. The research aims to determine if this treatment approach can reduce the rate of major bacterial infections compared to standard care alone, potentially offering better protection for patients whose cancer treatments have weakened their immune systems.

This study is testing preventive treatments to reduce taste changes (called dysgeusia) that can occur in patients with relapsed or treatment-resistant multiple myeloma who are receiving talquetamab therapy. The research focuses on finding ways to prevent or minimize these taste-related side effects before they occur, which could help patients maintain better quality of life and continue their cancer treatment more comfortably.

This study is testing a combination of curcumin and piperine supplements in patients with early-stage prostate cancer on active surveillance, or those being monitored for conditions that may lead to multiple myeloma (MGUS or low-risk smoldering myeloma). The research aims to determine if these natural compounds can help prevent disease progression in patients who are currently being watched rather than actively treated.

This study examines the drug siltuximab for treating serious side effects called cytokine release syndrome and neurological problems that can occur in Multiple Myeloma patients receiving CAR-T cell therapy. The research aims to reduce the severity of these potentially dangerous complications, which could make CAR-T cell treatment safer and more tolerable for patients with blood cancers.

This study compares teclistamab (a single medication) versus standard combination treatments in patients with multiple myeloma that has returned or stopped responding to previous therapies. The research is unique because it tests whether teclistamab alone can work as well as or better than current multi-drug combinations, potentially offering patients an effective treatment option with fewer medications.

This study examines psilocybin therapy combined with brief counseling for patients with advanced cancer (stage 3 or 4) who are experiencing anxiety, depression, and concerns about meaning and death. The research compares the effects of psilocybin to an active comparison treatment to determine how this approach might help reduce psychological distress in people facing serious cancer diagnoses.

This study compares three different combinations of cancer drugs (including bortezomib, lenalidomide, dexamethasone, and daratumumab) for treating newly diagnosed multiple myeloma in patients who are not healthy enough for stem cell transplant. The research will help doctors determine which drug combination works best to shrink and control multiple myeloma in frail or intermediate-fit patients, potentially leading to more personalized treatment approaches based on individual patient health status.

This study examines whether a prehabilitation program combining exercise and dietary guidelines can help older adults (60 years and older) with Multiple Myeloma prepare for autologous stem cell transplantation. The research is unique because it specifically focuses on improving physical function in older patients before their transplant, which may lead to better recovery outcomes and reduced complications after the procedure.

This study follows patients with multiple myeloma who previously received cilta-cel, a treatment that uses the patient's own immune cells that have been genetically modified to fight cancer cells. The study focuses on tracking the long-term safety of this treatment over many years to better understand any delayed side effects and help doctors provide the best care for future multiple myeloma patients.

This study tests venetoclax combined with isatuximab and dexamethasone for patients with relapsed or refractory multiple myeloma who have a specific genetic change called t(11;14). This unique combination targets cancer cells in multiple ways and may offer new hope for multiple myeloma patients whose cancer has returned or stopped responding to previous treatments.

This study is testing a mobile app called THRIVE-M that provides psychological support for adults with multiple myeloma who are receiving treatment or maintenance therapy. The app is designed to help improve quality of life, reduce psychological distress, and decrease fatigue compared to standard care alone, potentially offering patients a convenient way to access mental health support during their cancer treatment.

This study is testing CCS1477 (inobrodib), a new cancer drug, in patients with blood cancers including multiple myeloma, non-Hodgkin lymphoma, acute myeloid leukemia, and myelodysplastic syndrome whose cancer has returned or not responded to standard treatments. The study will test CCS1477 alone and in combination with other cancer drugs like venetoclax, azacitidine, dexamethasone, and pomalidomide to find the safest and most effective treatment approach for patients with these blood cancers.

This study is testing a new drug called SX-682 combined with three standard multiple myeloma medications (carfilzomib, daratumumab-hyaluronidase, and dexamethasone) in patients whose multiple myeloma has returned after treatment or has not responded to previous therapies. SX-682 works by blocking certain sites on cells that normally suppress the immune system, potentially allowing the body's natural defenses to better fight cancer cells when combined with proven multiple myeloma treatments.